mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern

作者：Wang, Haomeng; Chen, Zhao; Wang, Zhenghua; Li, Jin; Yan, Zhihong; Yuan, Jinbo; Zhu, Airu; Chen, Lan; Liu, Ye; Hu, Chenlong; Zhu, Ali; Li, Guowei; Li, Yuehu; Deng, Jie; Ma, Liqiao; Sui, Xiuwen; Miao, Wei; Li, Junqiang; Zheng, Xiuyu; Piao, Jinhua; Yao, Yanfeng; Rao, Juhong; Shan, Chao; Yuan, Zhiming; Zhao, Jincun; Zhu, Tao

来源：Emerging Microbes & Infections, 2022, 11(1): 1550-1553.

DOI：10.1080/22221751.2022.2081616

• COVID-19
• mRNA
• Beta
• Omicron
• vaccine

In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.

• 单位
  1; 中国科学院; 广州医学院